SGP SpyGlass Pharma, Inc. Common Stock
USHealthcareAs of 2026-10-08
Why SGP matters now
SpyGlass Pharma, Inc. Common Stock (SGP) is a US stock in Healthcare. The latest InvestLog snapshot shows $24.62 with +3.01% on the session and $823.1M in market capitalization; recent performance reads 1-month -11.79% and YTD -29.17%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-13.8M, and EPS of $-0.69. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.8%.
The latest indexable market news headline is "SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $62.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.49
P/S
0.00
EV/EBITDA
-15.01
DCF Value
$2.77
FCF Yield
-3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-123.5%
ROA
-10.2%
ROIC
-11.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-13.8M | $-0.69 |
| Q4 2025 | $0.00 | $-12.6M | $-0.38 |
| FY 2025 | $0.00 | $-39.9M | $-1.19 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$62.00
Target (Median)
$62.00
Target Range
$62.00 - $62.00
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.34
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.